Literature DB >> 18800066

NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.

Linda S Brady1, Lois Winsky, Wayne Goodman, Mary Ellen Oliveri, Ellen Stover.   

Abstract

There is an urgent need to transform basic research discoveries into tools for treatment and prevention of mental illnesses. This article presents an overview of the National Institute of Mental Health (NIMH) programs and resources to address the challenges and opportunities in psychiatric drug development starting at the point of discovery through the early phases of translational research. We summarize NIMH and selected National Institutes of Health (NIH) efforts to stimulate translation of basic and clinical neuroscience findings into novel targets, models, compounds, and strategies for the development of innovative therapeutics for psychiatric disorders. Examples of collaborations and partnerships among NIMH/NIH, academia, and industry are highlighted.

Entities:  

Mesh:

Year:  2008        PMID: 18800066      PMCID: PMC2917632          DOI: 10.1038/npp.2008.125

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

1.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

2.  From animal models to model animals.

Authors:  Thomas R Insel
Journal:  Biol Psychiatry       Date:  2007-12-15       Impact factor: 13.382

3.  2007 FDA drug approvals: a year of flux.

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

4.  Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.

Authors:  L Michelle Lewis; Douglas Sheffler; Richard Williams; Thomas M Bridges; J Phillip Kennedy; J T Brogan; Matthew J Mulder; Lyndsey Williams; Natalia T Nalywajko; Colleen M Niswender; Charles D Weaver; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

5.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

6.  Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor.

Authors:  Steve Titus; Susanne Neumann; Wei Zheng; Noel Southall; Sam Michael; Carleen Klumpp; Adam Yasgar; Paul Shinn; Craig J Thomas; James Inglese; Marvin C Gershengorn; Christopher P Austin
Journal:  J Biomol Screen       Date:  2008-01-23

7.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

8.  Identification of a potent new chemotype for the selective inhibition of PDE4.

Authors:  Amanda P Skoumbourdis; Ruili Huang; Noel Southall; William Leister; Vicky Guo; Ming-Hsuang Cho; James Inglese; Marshall Nirenberg; Christopher P Austin; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2008-01-11       Impact factor: 2.823

Review 9.  How has DISC1 enabled drug discovery?

Authors:  Qi Wang; Hanna Jaaro-Peled; Akira Sawa; Nicholas J Brandon
Journal:  Mol Cell Neurosci       Date:  2007-10-23       Impact factor: 4.314

10.  Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects.

Authors:  Jessica E Malberg; Brian Platt; Stacey J Sukoff Rizzo; Robert H Ring; Irwin Lucki; Lee E Schechter; Sharon Rosenzweig-Lipson
Journal:  Neuropsychopharmacology       Date:  2007-03-07       Impact factor: 7.853

View more
  4 in total

1.  Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.

Authors:  Jeffrey L Cummings; John Ringman; Karen Metz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

3.  Drug development in pediatric psychiatry: current status, future trends.

Authors:  John S March; Joerg M Fegert
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-02-07       Impact factor: 3.033

4.  The innovative medicines initiative: a public private partnership model to foster drug discovery.

Authors:  Elisabetta Vaudano
Journal:  Comput Struct Biotechnol J       Date:  2013-11-27       Impact factor: 7.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.